PATENT CLAIM ANALYSIS

Application Number: 16074727
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "176000"]

Abstract:
Disclosed are a steroidal compound as shown in formula (I) and a drug composition containing the same, or a crystal form, a pharmaceutically acceptable salt, a hydrate or solvate, a stereoisomer, a prodrug, a metabolite or an isotopic variant thereof. The compound can be used as a CYP17 enzyme inhibitor, and has better pharmacokinetic parameters, which can improve drug concentration of the compound in an animal, thereby improving the efficacy and safety of the drug, and in turn the compound may be applied in the preparation of the drug for treating CYP17 enzyme-related diseases (such as prostate cancer).

Claim (Index 21):
The compound according to  claim 15 , wherein X 1  and X 2  are independently selected from a methyl or an ethyl group, which are substituted with one or more deuteriums.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 96.0
- Lexical Diversity: 1.72727
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13145997', '13876646', '15159117', '13884676', '14598721']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7595413556196613
- 35 USC 102 Novelty (BERT): 0.5086503690423229
- Combined Prediction Score: 0.7344522569619275
- Mean Citation Score: 246.050686
- Max Citation Score: 252.5395
- Similarity Product: 168.5351088885665

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test